Compugen to Present at Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy firm, announced its participation in several upcoming investor conferences. Notable events include the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 AM ET, and the Jefferies Virtual Healthcare Conference on November 18, 2021, with a recording available from 3:00 AM ET. Additional engagements include the Truist Securities SITC Breakfast on November 13, JMP Securities Virtual C-Suite on November 29, and the JMP Securities Virtual Hematology Oncology Summit on December 7. For more details, visit www.cgen.com.
- None.
- None.
HOLON, ISRAEL, Nov. 8, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that management will present at the following investor conferences.
Event: Stifel 2021 Virtual Healthcare Conference
Date: Tuesday, November 16, 2021
Fireside Chat Time: 11:20 AM ET
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
Event: Jefferies Virtual Healthcare Conference
Date: Thursday, November 18, 2021
Fireside Chat: Recording available from 3:00 AM ET (8:00 AM GMT)
A recording will be accessible on the Investor Relations section of the Compugen website at www.cgen.com
In addition, Compugen management will be participating at the Truist Securities SITC Breakfast on Saturday November 13, 2021, at the JMP Securities Virtual C-Suite on Monday November 29, 2021, and the JMP Securities Virtual Hematology Oncology Summit on Tuesday December 7, 2021.
About Compugen
Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a potentially first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies as a single agent and in dual, and triple combinations. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Partnered programs include bapotulimab, a therapeutic antibody in Phase 1 development targeting ILDR2 licensed to Bayer under a research and discovery collaboration and license agreement, and AZD2936, a TIGIT/PD-1 bispecific in Phase 1 development derived from COM902 through a license agreement with AstraZeneca for the development of bispecific and multi-specific antibodies. Compugen's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com
Company contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
Investor Relations contact:
John Mullaly
LifeSci Advisors, LLC
Email: jmullaly@lifesciadvisors.com
Tel: +1 (617) 429-3548
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-upcoming-investor-conferences-301418299.html
SOURCE Compugen Ltd.
FAQ
What investor conferences is Compugen (CGEN) participating in November 2021?
When is the Stifel 2021 Virtual Healthcare Conference for Compugen (CGEN)?
Where can I access the recordings of Compugen's investor presentations?
What is Compugen's lead product candidate in cancer immunotherapy?
What is the ticker symbol for Compugen?
